Sam Kintz, M.B.A.

Sam Kintz, M.B.A.

Former President and Chief Executive OfficeratEnliven Therapeutics· In proxies 2022–2025

Pay in FY2025Enliven Therapeutics stock -31.6% the same year

Sam Kintz, M.B.A. was paid $8.9M in FY2025 (Dec). Enliven Therapeutics stock fell 31.6% that year.

Pay$100 in the stock at the end of FY21 → $105
Pay is from the Summary Compensation Table of each Enliven Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Enliven TherapeuticsPublic company · 4 yr
    • Former President and Chief Executive Officer2022 – Present · 4 yrStock in role +357%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?